Fintel on MSN8d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation
Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
Nasdaq16d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation
a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines. Fintel is one of ...
Yahoo Finance6d
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media ...
Investing8d
William Blair starts Mersana stock with Outperform rating
ADCs have recently seen increased interest, and Mersana's lead ADC candidate, Emiltatug ledadotin (Emi-Le), has shown promising results in early clinical trials. According to InvestingPro data ...
manilatimes6d
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the "Investors & Media” ...